Muscle overexpression of Klf15 via an AAV8-Spc5-12 construct does not provide benefits in spinal muscular atrophy mice.


Journal

Gene therapy
ISSN: 1476-5462
Titre abrégé: Gene Ther
Pays: England
ID NLM: 9421525

Informations de publication

Date de publication:
11 2019
Historique:
received: 28 07 2019
accepted: 27 03 2020
revised: 19 03 2020
pubmed: 22 4 2020
medline: 19 8 2021
entrez: 22 4 2020
Statut: ppublish

Résumé

Spinal muscular atrophy (SMA) is a neuromuscular disease caused by loss of the survival motor neuron (SMN) gene. While there are currently two approved gene-based therapies for SMA, availability, high cost, and differences in patient response indicate that alternative treatment options are needed. Optimal therapeutic strategies will likely be a combination of SMN-dependent and -independent treatments aimed at alleviating symptoms in the central nervous system and peripheral muscles. Krüppel-like factor 15 (KLF15) is a transcription factor that regulates key metabolic and ergogenic pathways in muscle. We have recently reported significant downregulation of Klf15 in muscle of presymptomatic SMA mice. Importantly, perinatal upregulation of Klf15 via transgenic and pharmacological methods resulted in improved disease phenotypes in SMA mice, including weight and survival. In the current study, we designed an adeno-associated virus serotype 8 (AAV8) vector to overexpress a codon-optimized Klf15 cDNA under the muscle-specific Spc5-12 promoter (AAV8-Klf15). Administration of AAV8-Klf15 to severe Taiwanese Smn

Identifiants

pubmed: 32313099
doi: 10.1038/s41434-020-0146-8
pii: 10.1038/s41434-020-0146-8
pmc: PMC7674152
doi:

Substances chimiques

KLF15 protein, human 0
Klf15 protein, mouse 0
Kruppel-Like Transcription Factors 0
Survival of Motor Neuron 1 Protein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

505-515

Subventions

Organisme : Medical Research Council
ID : MR/R025312/1
Pays : United Kingdom

Références

Crawford TO, Pardo CA. The neurobiology of childhood spinal muscular atrophy. Neurobiol Dis. 1996;3:97–110.
pubmed: 9173917
Pearn J. Classification of spinal muscular atrophies. Lancet. 1980;1:919–22.
pubmed: 6103267
Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155–65.
pubmed: 7813012
Schrank B, Götz R, Gunnersen JM, Ure JM, Toyka KV, Smith AG, et al. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci USA. 1997;94:9920–5.
pubmed: 9275227
Monani UR, Lorson CL, Parsons DW, Prior TW, Androphy EJ, Burghes AH, et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet. 1999;8:1177–83.
pubmed: 10369862
Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA. 1999;96:6307–11.
pubmed: 10339583
Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, Munnich A, et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet. 1997;16:265–9.
pubmed: 9207792
Chiriboga CA. Nusinersen for the treatment of spinal muscular atrophy. Expert Rev Neurother. 2017;17:955–62.
pubmed: 28884620
Singh NN, Lee BM, DiDonato CJ, Singh RN. Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy. Future Med Chem. 2015;7:1793–808.
pubmed: 26381381 pmcid: 4660980
Hoy SM. Onasemnogene abeparvovec: first global approval. Drugs. 2019;79:1255–62.
pubmed: 31270752
Wood MJA, Talbot K, Bowerman M. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape. Hum Mol Genet. 2017;26:R151–9.
pubmed: 28977438
Bowerman M, Becker CG, Yáñez-Muñoz RJ, Ning K, Wood MJA, Gillingwater TH, et al. Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Dis Model Mech. 2017;10:943–54.
pubmed: 28768735 pmcid: 5560066
Gidaro T, Servais L. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps. Dev Med Child Neurol. 2019;61:19–24.
pubmed: 30221755
Lipnick SL, Agniel DM, Aggarwal R, Makhortova NR, Finlayson SG, Brocato A, et al. Systemic nature of spinal muscular atrophy revealed by studying insurance claims. PLoS ONE. 2019;14:e0213680.
pubmed: 30870495 pmcid: 6417721
Bowerman M. Funding for spinal muscular atrophy research must continue. Future Neurol. 2019;14:FNL10.
Boyer JG, Ferrier A, Kothary R. More than a bystander: the contributions of intrinsic skeletal muscle defects in motor neuron diseases. Front Physiol. 2013;4:356.
pubmed: 24391590 pmcid: 3866803
Bowerman M, Murray LM, Scamps F, Schneider BL, Kothary R, Raoul C. Pathogenic commonalities between spinal muscular atrophy and amyotrophic lateral sclerosis: converging roads to therapeutic development. Eur J Med Genet. 2018;61:685–98.
pubmed: 29313812
Walter LM, Deguise M-O, Meijboom KE, Betts CA, Ahlskog N, van Westering TLE, et al. Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain amino acid signaling improve disease phenotypes in spinal muscular atrophy mice. EBioMedicine. 2018;31:226–42.
pubmed: 29735415 pmcid: 6013932
Morrison-Nozik A, Anand P, Zhu H, Duan Q, Sabeh M, Prosdocimo DA, et al. Glucocorticoids enhance muscle endurance and ameliorate Duchenne muscular dystrophy through a defined metabolic program. Proc Natl Acad Sci USA. 2015;112:E6780–9.
pubmed: 26598680
Haldar SM, Jeyaraj D, Anand P, Zhu H, Lu Y, Prosdocimo DA, et al. Kruppel-like factor 15 regulates skeletal muscle lipid flux and exercise adaptation. Proc Natl Acad Sci USA. 2012;109:6739–44.
pubmed: 22493257
Gray S, Wang B, Orihuela Y, Hong E-G, Fisch S, Haldar S, et al. Regulation of gluconeogenesis by Krüppel-like factor 15. Cell Metab. 2007;5:305–12.
pubmed: 17403374 pmcid: 1892530
Jeyaraj D, Scheer FAJL, Ripperger JA, Haldar SM, Lu Y, Prosdocimo DA, et al. Klf15 orchestrates circadian nitrogen homeostasis. Cell Metab. 2012;15:311–23.
pubmed: 22405069 pmcid: 3299986
El-Brolosy MA, Stainier DYR. Genetic compensation: a phenomenon in search of mechanisms. PLOS Genet. 2017;13:e1006780.
pubmed: 28704371 pmcid: 5509088
Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM, Tsai CH, et al. A mouse model for spinal muscular atrophy. Nat Genet. 2000;24:66–70.
pubmed: 10615130
Bowerman M, Murray LM, Beauvais A, Pinheiro B, Kothary R. A critical SMN threshold in mice dictates onset of an intermediate spinal muscular atrophy phenotype associated with a distinct neuromuscular junction pathology. Neuromuscul Disord NMD. 2012;22:263–76.
pubmed: 22071333
Gombash Lampe SE, Kaspar BK, Foust KD. Intravenous injections in neonatal mice. J Vis Exp. 2014;93:e52037. https://doi.org/10.3791/52037 .
doi: 10.3791/52037
Li X, Eastman EM, Schwartz RJ, Draghia-Akli R. Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat Biotechnol. 1999;17:241.
pubmed: 10096290
Blau HM, Pavlath GK, Hardeman EC, Chiu CP, Silberstein L, Webster SG, et al. Plasticity of the differentiated state. Science. 1985;230:758–66.
pubmed: 2414846
Radonić A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A. Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun. 2004;313:856–62.
pubmed: 14706621
Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676–82.
pubmed: 22743772
Foster H, Sharp PS, Athanasopoulos T, Trollet C, Graham IR, Foster K, et al. Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. Mol Ther J Am Soc Gene Ther. 2008;16:1825–32.
Kaifer KA, Villalón E, Osman EY, Glascock JJ, Arnold LL, Cornelison DDW, et al. Plastin-3 extends survival and reduces severity in mouse models of spinal muscular atrophy. JCI Insight. 2017;2:e89970.
pubmed: 28289706 pmcid: 5333955
Osman EY, Rietz A, Kline RA, Cherry JJ, Hodgetts KJ, Lorson CL, et al. Intraperitoneal delivery of a novel drug-like compound improves disease severity in severe and intermediate mouse models of spinal muscular atrophy. Sci Rep. 2019;9:1633.
pubmed: 30733501 pmcid: 6367425
Zhao Y, Song W, Wang L, Rane MJ, Han F, Cai L. Multiple roles of KLF15 in the heart: Underlying mechanisms and therapeutic implications. J Mol Cell Cardiol. 2019;129:193–6.
pubmed: 30831134
Takashima M, Ogawa W, Hayashi K, Inoue H, Kinoshita S, Okamoto Y, et al. Role of KLF15 in regulation of hepatic gluconeogenesis and metformin action. Diabetes. 2010;59:1608–15.
pubmed: 20393151 pmcid: 2889759
Hirata Y, Nomura K, Senga Y, Okada Y, Kobayashi K, Okamoto S, et al. Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis. JCI Insight. 2019;4. https://doi.org/10.1172/jci.insight.124952 .
Quattrocelli M, Barefield DY, Warner JL, Vo AH, Hadhazy M, Earley JU, et al. Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy. J Clin Invest. 2017;127:2418–32.
pubmed: 28481224 pmcid: 5451235
Sands MS. AAV-mediated liver-directed gene therapy. Methods Mol Biol. 2011;807:141–57.
pubmed: 22034029 pmcid: 4118577
Wijngaarde CA, Blank AC, Stam M, Wadman RI, van den Berg LH, van der Pol WL. Cardiac pathology in spinal muscular atrophy: a systematic review. Orphanet J Rare Dis. 2017;12:67.
pubmed: 28399889 pmcid: 5387385
Szunyogova E, Zhou H, Maxwell GK, Powis RA, Francesco M, Gillingwater TH, et al. Survival Motor Neuron (SMN) protein is required for normal mouse liver development. Sci Rep. 2016;6:34635.
pubmed: 27698380 pmcid: 5048144
Penaud-Budloo M, François A, Clément N, Ayuso E. Pharmacology of recombinant adeno-associated virus production. Mol Ther Methods Clin Dev. 2018;8:166–80.
pubmed: 29687035 pmcid: 5908265
Reichel FF, Dauletbekov DL, Klein R, Peters T, Ochakovski GA, Seitz IP, et al. AAV8 can induce innate and adaptive immune response in the primate eye. Mol Ther. 2017;25:2648–60.
pubmed: 28970046 pmcid: 5768589
Wang L, Calcedo R, Wang H, Bell P, Grant R, Vandenberghe LH, et al. The pleiotropic effects of natural AAV infections on liver-directed gene transfer in Macaques. Mol Ther. 2010;18:126–34.
pubmed: 19888196
Deguise M-O, Kothary R. New insights into SMA pathogenesis: immune dysfunction and neuroinflammation. Ann Clin Transl Neurol. 2017;4:522–30.
pubmed: 28695153 pmcid: 5497530
Deguise M-O, De Repentigny Y, McFall E, Auclair N, Sad S, Kothary R. Immune dysregulation may contribute to disease pathogenesis in spinal muscular atrophy mice. Hum Mol Genet. 2017;26:801–19.
pubmed: 28108555 pmcid: 5409095
Butterfield TA, Best TM, Merrick MA. The dual roles of neutrophils and macrophages in inflammation: a critical balance between tissue damage and repair. J Athl Train. 2006;41:457–65.
pubmed: 17273473 pmcid: 1748424
Hohlfeld R, Kerschensteiner M, Meinl E. Dual role of inflammation in CNS disease. Neurology. 2007;68:S58–63. discussion S91-96
pubmed: 17548571
Yang W, Hu P. Skeletal muscle regeneration is modulated by inflammation. J Orthop Transl. 2018;13:25–32.

Auteurs

Nina Ahlskog (N)

Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.
Department of Paediatrics, University of Oxford, Oxford, UK.

Daniel Hayler (D)

AGCTlab.org, Centre of Gene and Cell Therapy, Centre for Biomedical Sciences, Department of Biological Sciences, Royal Holloway University of London, Egham Hill, Egham, Surrey, UK.

Anja Krueger (A)

Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.

Sabrina Kubinski (S)

Institute of Neuroanatomy and Cell Biology, Hannover Medical School, Hannover, Germany.
Center of Systems Neuroscience, Hannover, Germany.

Peter Claus (P)

Institute of Neuroanatomy and Cell Biology, Hannover Medical School, Hannover, Germany.
Center of Systems Neuroscience, Hannover, Germany.

Suzan M Hammond (SM)

Department of Paediatrics, University of Oxford, Oxford, UK.
MDUK Oxford Neuromuscular Centre, University of Oxford, Oxford, UK.

Matthew J A Wood (MJA)

Department of Paediatrics, University of Oxford, Oxford, UK.
MDUK Oxford Neuromuscular Centre, University of Oxford, Oxford, UK.

Rafael J Yáñez-Muñoz (RJ)

AGCTlab.org, Centre of Gene and Cell Therapy, Centre for Biomedical Sciences, Department of Biological Sciences, Royal Holloway University of London, Egham Hill, Egham, Surrey, UK.

Melissa Bowerman (M)

Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK. m.bowerman@keele.ac.uk.
School of Medicine, Keele University, Staffordshire, UK. m.bowerman@keele.ac.uk.
Wolfson Centre for Inherited Neuromuscular Disease, RJAH Orthopaedic Hospital, Oswestry, UK. m.bowerman@keele.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH